Cent

Cent employs a proprietary CCNM™ early-detection protocol and converts multimodal diagnostic and biomarker data into Tru10™ organ-wise health risk scores to prioritise risk and intervention. The company offers next-generation sequencing and polygenic risk modelling as a genetics add-on, provides at-home blood and urine collection by certified phlebotomists, delivers doctor-reviewed integrated health reports with personalised plans, and supports retesting and longitudinal tracking to monitor improvements.